Pub Date : 2025-11-05DOI: 10.1016/j.eujim.2025.102580
Yang Xie , Yiting Li , Peng Zhang , Baichuan Xu , Beibei Bao , Zifan Cheng , Tao Chen , Jiansheng Li
Introduction
Early identification and monitoring of preserved ratio impaired spirometry (PRISm) population and suitable intervention can reduce the incidence rate of chronic obstructive pulmonary disease (COPD) and delay the disease process. Although Traditional Chinese medicine (TCM) has been used to treat COPD for many years, few data are available for the PRISm population. This study aims to evaluate the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD.
Methods
This is a multicenter, randomized, double-blind, placebo-controlled trial targeting the PRISm population. One thousand one hundred PRISm patients will be randomly divided into two groups, with the experimental group receiving Bufei granules and the control group receiving placebo granules. The treatment regimen is to take one packet after meals, twice daily, for a period of two years. The main outcome is the incidence rate of COPD, and the secondary outcomes are lung function, COPD screening score, quality of life, clinical symptoms, 6-minute walking distance (6MWD), dyspnea score, biochemical indicators, and economic evaluation. Blood and urine routine tests, liver and kidney function tests, electrocardiogram, and chest computed tomography scans will be employed as safety indicators for the trial, with any adverse events occurring during the trial period being accurately recorded. The planned observation duration per patient is 2 years and will be followed up every 6 months.
Discussion
This study will provide evidence to assess the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD. It is expected that PRISm volunteers will show a reduced incidence rate and will exhibit improved lung function and quality of life. The data will be released after the research is completed.
{"title":"Effectiveness and safety of Bufei granules in treatment of preserved ratio impaired spirometry: Study protocol for a randomized controlled trial","authors":"Yang Xie , Yiting Li , Peng Zhang , Baichuan Xu , Beibei Bao , Zifan Cheng , Tao Chen , Jiansheng Li","doi":"10.1016/j.eujim.2025.102580","DOIUrl":"10.1016/j.eujim.2025.102580","url":null,"abstract":"<div><h3>Introduction</h3><div>Early identification and monitoring of preserved ratio impaired spirometry (PRISm) population and suitable intervention can reduce the incidence rate of chronic obstructive pulmonary disease (COPD) and delay the disease process. Although Traditional Chinese medicine (TCM) has been used to treat COPD for many years, few data are available for the PRISm population. This study aims to evaluate the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD.</div></div><div><h3>Methods</h3><div>This is a multicenter, randomized, double-blind, placebo-controlled trial targeting the PRISm population. One thousand one hundred PRISm patients will be randomly divided into two groups, with the experimental group receiving Bufei granules and the control group receiving placebo granules. The treatment regimen is to take one packet after meals, twice daily, for a period of two years. The main outcome is the incidence rate of COPD, and the secondary outcomes are lung function, COPD screening score, quality of life, clinical symptoms, 6-minute walking distance (6MWD), dyspnea score, biochemical indicators, and economic evaluation. Blood and urine routine tests, liver and kidney function tests, electrocardiogram, and chest computed tomography scans will be employed as safety indicators for the trial, with any adverse events occurring during the trial period being accurately recorded. The planned observation duration per patient is 2 years and will be followed up every 6 months.</div></div><div><h3>Discussion</h3><div>This study will provide evidence to assess the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD. It is expected that PRISm volunteers will show a reduced incidence rate and will exhibit improved lung function and quality of life. The data will be released after the research is completed.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov registration number: NCT06375824.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"81 ","pages":"Article 102580"},"PeriodicalIF":1.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1016/j.eujim.2025.102579
Marjorie Navarro
Introduction
There is a lack of information on bodywork, such as acupuncture, in conjunction with psychedelic medicine. The objective of this pilot study was twofold: to assess the feasibility and tolerability of acupuncture in a group setting as an integrative somatic intervention following a ketamine experience for psychospiritual growth.
Methods
Participants (n = 15) were enrolled in a group ketamine experience followed by acupuncture one hour after ketamine administration. An optional Participant Feedback Form was administered after the session; responses were reported descriptively as acceptability signals and were not analyzed as formal qualitative data. The Experienced Integration Scale (EIS) was administered within 72 h after the intervention and again after 3 months.
Results
Of 88 people who requested an eligibility review, 17 were enrolled, filling the study in 20 days. Fifteen attended their scheduled sessions, yielding an 88% retention rate. Initial EIS scores ranged from 45% to 100% (mean 74%), with follow-up scores obtained from 6 participants after 3 months. Feedback from 5 participants described the acupuncture as grounding, calming, and valuable, with one suggesting more time for treatment. Together, these findings suggest that acupuncture after a ketamine experience is feasible and well-tolerated in healthy volunteers seeking psychospiritual growth.
Conclusion
Participant enrollment and retention rates show substantial patient interest in utilizing acupuncture and sound meditation to support psychedelic therapy. Further research is warranted to explore the potential benefits of acupuncture in conjunction with psychedelic therapy. Such research may inform care for individuals who are currently using these therapies separately, as well as those seeking more integrated approaches.
Registration
The study is registered at the United States Clinical Trial Registry (NCT06070090).
Funding
No funding agencies in the public, commercial, or not-for-profit sectors.
{"title":"Group acupuncture following a psychedelic ketamine experience: An integrative medicine pilot study","authors":"Marjorie Navarro","doi":"10.1016/j.eujim.2025.102579","DOIUrl":"10.1016/j.eujim.2025.102579","url":null,"abstract":"<div><h3>Introduction</h3><div>There is a lack of information on bodywork, such as acupuncture, in conjunction with psychedelic medicine. The objective of this pilot study was twofold: to assess the feasibility and tolerability of acupuncture in a group setting as an integrative somatic intervention following a ketamine experience for psychospiritual growth.</div></div><div><h3>Methods</h3><div>Participants (<em>n</em> = 15) were enrolled in a group ketamine experience followed by acupuncture one hour after ketamine administration. An optional Participant Feedback Form was administered after the session; responses were reported descriptively as acceptability signals and were not analyzed as formal qualitative data. The Experienced Integration Scale (EIS) was administered within 72 h after the intervention and again after 3 months.</div></div><div><h3>Results</h3><div>Of 88 people who requested an eligibility review, 17 were enrolled, filling the study in 20 days. Fifteen attended their scheduled sessions, yielding an 88% retention rate. Initial EIS scores ranged from 45% to 100% (mean 74%), with follow-up scores obtained from 6 participants after 3 months. Feedback from 5 participants described the acupuncture as grounding, calming, and valuable, with one suggesting more time for treatment. Together, these findings suggest that acupuncture after a ketamine experience is feasible and well-tolerated in healthy volunteers seeking psychospiritual growth.</div></div><div><h3>Conclusion</h3><div>Participant enrollment and retention rates show substantial patient interest in utilizing acupuncture and sound meditation to support psychedelic therapy. Further research is warranted to explore the potential benefits of acupuncture in conjunction with psychedelic therapy. Such research may inform care for individuals who are currently using these therapies separately, as well as those seeking more integrated approaches.</div></div><div><h3>Registration</h3><div>The study is registered at the United States Clinical Trial Registry (NCT06070090).</div></div><div><h3>Funding</h3><div>No funding agencies in the public, commercial, or not-for-profit sectors.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102579"},"PeriodicalIF":1.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nurses experience a range of occupational stressors, including night shifts and excessive workloads. These factors significantly increase the likelihood of nurses developing chronic stress, anxiety, fatigue, and sleep disorders. Although numerous studies have proposed aromatherapy interventions as potential strategies to alleviate these health concerns, the evidence regarding their effectiveness remains inconclusive. This study aims to evaluate the effectiveness of aromatherapy on stress, anxiety, fatigue, and sleep disorders among nurses, and identify key factors for effective programs.
Methods
We systematically searched six electronic databases, supplemented by manual searches of Google Scholar and reference lists. The search covered the period from the inception of each database up until March 2025. Two researchers independently performed study selection and data extraction. The risk of bias of the included studies was evaluated using the RoB 2.0 tool. The quality of evidence for each outcome was graded using the GRADE framework. A random-effects model was used to perform the meta-analysis. Subgroup analysis was conducted to identify potential moderating variables.
Results
A total of 19 studies were included in this systematic review, 12 of which were RCTs. Meta-analysis results indicated that aromatherapy significantly alleviated stress (SMD= -0.74, 95 % CI [-1.12, -0.35], Z = 3.76, P = 0.0002) and fatigue symptoms (SMD = -0.76, 95 % CI [-1.10, -0.42], P < 0.0001) among nurses. Short-term interventions (≤1 week) produced a larger effect size (SMD =-0.80, 95 % CI [-1.47, -0.14], P = 0.02) than longer-term interventions (>1 week) (SMD= -0.61, 95 % CI [-0.95, -0.26], P = 0.0006), possibly due to olfactory adaptation or metabolic regulation. In contrast, the overall effect on anxiety reduction was not statistically significant (SMD =-0.89, 95 % CI [-2.21, 0.42], P = 0.18), and evidence regarding sleep quality improvement remained inconclusive.
Conclusion
Aromatherapy effectively reduces stress and fatigue in nurses, making it a valuable addition to workplace wellness programs.
护士经历了一系列的职业压力源，包括夜班和过度的工作量。这些因素显著增加了护士出现慢性压力、焦虑、疲劳和睡眠障碍的可能性。尽管许多研究已经提出芳香疗法干预作为缓解这些健康问题的潜在策略，但关于其有效性的证据仍然不确定。本研究旨在评估芳香疗法对护士压力、焦虑、疲劳和睡眠障碍的效果，并找出有效方案的关键因素。方法系统检索6个电子数据库，并辅以人工检索b谷歌Scholar和参考文献目录。搜索涵盖了从每个数据库建立到2025年3月的时期。两位研究者独立进行了研究选择和数据提取。使用RoB 2.0工具评估纳入研究的偏倚风险。使用GRADE框架对每个结果的证据质量进行分级。采用随机效应模型进行meta分析。进行亚组分析以确定潜在的调节变量。结果本系统综述共纳入19项研究，其中12项为随机对照试验。meta分析结果显示，芳香疗法显著缓解了护士的压力（SMD= -0.74, 95% CI [-1.12, -0.35], Z = 3.76, P = 0.0002）和疲劳症状（SMD= -0.76, 95% CI [-1.10, -0.42], P < 0.0001）。短期干预（≤1周）产生的效应量（SMD= -0.80, 95% CI [-1.47, -0.14], P = 0.02）大于长期干预（>；1周）（SMD= -0.61, 95% CI [-0.95, -0.26], P = 0.0006），可能是嗅觉适应或代谢调节所致。相比之下，减少焦虑的总体效果没有统计学意义（SMD =-0.89, 95% CI [-2.21, 0.42], P = 0.18），关于睡眠质量改善的证据仍然没有定论。结论芳香疗法有效地减轻了护士的压力和疲劳，使其成为工作场所健康计划的宝贵补充。
{"title":"Effectiveness of aromatherapy on stress, anxiety, fatigue, and sleep quality among frontline hospital nurses: A systematic review and meta-analysis","authors":"Linfang Xu , Yanan Deng , Lan Zeng , Ruben Martin-Payo , Wei Peng , Chen Qiu , Keqi Chen , Fengying Zhang","doi":"10.1016/j.eujim.2025.102577","DOIUrl":"10.1016/j.eujim.2025.102577","url":null,"abstract":"<div><h3>Introduction</h3><div>Nurses experience a range of occupational stressors, including night shifts and excessive workloads. These factors significantly increase the likelihood of nurses developing chronic stress, anxiety, fatigue, and sleep disorders. Although numerous studies have proposed aromatherapy interventions as potential strategies to alleviate these health concerns, the evidence regarding their effectiveness remains inconclusive. This study aims to evaluate the effectiveness of aromatherapy on stress, anxiety, fatigue, and sleep disorders among nurses, and identify key factors for effective programs.</div></div><div><h3>Methods</h3><div>We systematically searched six electronic databases, supplemented by manual searches of Google Scholar and reference lists. The search covered the period from the inception of each database up until March 2025. Two researchers independently performed study selection and data extraction. The risk of bias of the included studies was evaluated using the RoB 2.0 tool. The quality of evidence for each outcome was graded using the GRADE framework. A random-effects model was used to perform the meta-analysis. Subgroup analysis was conducted to identify potential moderating variables.</div></div><div><h3>Results</h3><div>A total of 19 studies were included in this systematic review, 12 of which were RCTs. Meta-analysis results indicated that aromatherapy significantly alleviated stress (SMD= -0.74, 95 % CI [-1.12, -0.35], <em>Z</em> = 3.76, <em>P</em> = 0.0002) and fatigue symptoms (SMD = -0.76, 95 % CI [-1.10, -0.42], <em>P</em> < 0.0001) among nurses. Short-term interventions (≤1 week) produced a larger effect size (SMD =-0.80, 95 % CI [-1.47, -0.14], <em>P</em> = 0.02) than longer-term interventions (>1 week) (SMD= -0.61, 95 % CI [-0.95, -0.26], <em>P</em> = 0.0006), possibly due to olfactory adaptation or metabolic regulation. In contrast, the overall effect on anxiety reduction was not statistically significant (SMD =-0.89, 95 % CI [-2.21, 0.42], <em>P</em> = 0.18), and evidence regarding sleep quality improvement remained inconclusive.</div></div><div><h3>Conclusion</h3><div>Aromatherapy effectively reduces stress and fatigue in nurses, making it a valuable addition to workplace wellness programs.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102577"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-26DOI: 10.1016/j.eujim.2025.102576
Qianyang Zhu , Katherine Thomas , Sufan Ma , Junling Zhou , Qun Zhan , Ping Zang , Dan Wang , Yajie Zhang , Weina Zhu , Huijia Li , Jingjing Li , Qian Shi , Cairong Zhang
Introduction
Diminished ovarian reserve (DOR) significantly affects female fertility and overall health. Emerging evidence suggests that moxibustion treatment improves DOR. Methods: In this multicenter randomized controlled trial, 154 patients with kidney deficiency and blood stasis–type diminished ovarian reserve (KDBSDOR) were randomized to moxibustion (76 cases) or sham moxibustion (SM) (78 cases) . Participants underwent 12 weeks of treatment followed by 12 weeks of follow-up. During the treatment period, three 7-day courses of daily (sham) moxibustion were administered, concurrently with three 28-day courses of Femoston. The primary outcome was pregnancy rate at the end of the follow-up period. Secondary outcomes included clinical efficacy, changes in hormone levels, relevant scales, and findings of ultrasound monitoring. Data were analyzed between groups based on the intention-to-treat principle.
Results
The pregnancy rate was higher in the moxibustion group (17.1 %) than in the sham moxibustion group (3.9 %) [risk ratio (RR) = 5.53, 95 % confidence interval (CI) (1.13, 27.00)]. The moxibustion group showed significantly greater odds of clinical efficacy than the sham moxibustion group [odds ratio (OR) = 3.32, 95 % CI (1.76, 6.25)]. Relative to the sham moxibustion group, the moxibustion group showed a greater reduction in luteinizing hormone (LH) levels and greater increases in E2, anti-Müllerian hormone (AMH), antral follicle count (AFC), and endometrial thickness (all P < 0.05). After treatment, assessment scores decreased in both groups, with significant differences at different time points (P < 0.001). After 12 weeks of treatment, significant between-group differences were observed in the traditional Chinese medicine clinical symptom score [mean difference (MD) = -1.405, 95 % CI (–2.031, –0.779)], menstrual integral score [MD = -0.931, 95 % CI (–1.397, –0.464)], Kupperman index [MD = -3.004, 95 % CI (–4.209, –1.800)], and self-rating anxiety scale score [MD = -3.425, 95 % CI (–4.900, –1.950)]. The patients’ KDBS physiques improved. There was no significant difference in the incidence of adverse events between the two groups (p = 0.209).
Conclusions
Moxibustion effectively improved clinical symptoms, menstruation, ovarian reserve function, hormonal balance, and pregnancy rate in patients with KDBSDOR-related infertility. This treatment is a potential alternative for women with DOR.
For a video summary of this article, see the Supplemental file 2 available online.
{"title":"Efficacy and safety of moxibustion for diminished ovarian reserve infertility with kidney deficiency and blood stasis: a randomized controlled trial","authors":"Qianyang Zhu , Katherine Thomas , Sufan Ma , Junling Zhou , Qun Zhan , Ping Zang , Dan Wang , Yajie Zhang , Weina Zhu , Huijia Li , Jingjing Li , Qian Shi , Cairong Zhang","doi":"10.1016/j.eujim.2025.102576","DOIUrl":"10.1016/j.eujim.2025.102576","url":null,"abstract":"<div><h3>Introduction</h3><div>Diminished ovarian reserve (DOR) significantly affects female fertility and overall health. Emerging evidence suggests that moxibustion treatment improves DOR. <strong><em>Methods</em></strong>: In this multicenter randomized controlled trial, 154 patients with kidney deficiency and blood stasis–type diminished ovarian reserve (KDBSDOR) were randomized to moxibustion (76 cases) or sham moxibustion (SM) (78 cases) . Participants underwent 12 weeks of treatment followed by 12 weeks of follow-up. During the treatment period, three 7-day courses of daily (sham) moxibustion were administered, concurrently with three 28-day courses of Femoston. The primary outcome was pregnancy rate at the end of the follow-up period. Secondary outcomes included clinical efficacy, changes in hormone levels, relevant scales, and findings of ultrasound monitoring. Data were analyzed between groups based on the intention-to-treat principle.</div></div><div><h3>Results</h3><div>The pregnancy rate was higher in the moxibustion group (17.1 %) than in the sham moxibustion group (3.9 %) [risk ratio (RR) = 5.53, 95 % confidence interval (CI) (1.13, 27.00)]. The moxibustion group showed significantly greater odds of clinical efficacy than the sham moxibustion group [odds ratio (OR) = 3.32, 95 % CI (1.76, 6.25)]. Relative to the sham moxibustion group, the moxibustion group showed a greater reduction in luteinizing hormone (LH) levels and greater increases in E2, anti-Müllerian hormone (AMH), antral follicle count (AFC), and endometrial thickness (all <em>P</em> < 0.05). After treatment, assessment scores decreased in both groups, with significant differences at different time points (<em>P</em> < 0.001). After 12 weeks of treatment, significant between-group differences were observed in the traditional Chinese medicine clinical symptom score [mean difference (MD) = -1.405, 95 % CI (–2.031, –0.779)], menstrual integral score [MD = -0.931, 95 % CI (–1.397, –0.464)], Kupperman index [MD = -3.004, 95 % CI (–4.209, –1.800)], and self-rating anxiety scale score [MD = -3.425, 95 % CI (–4.900, –1.950)]. The patients’ KDBS physiques improved. There was no significant difference in the incidence of adverse events between the two groups (<em>p</em> = 0.209).</div></div><div><h3>Conclusions</h3><div>Moxibustion effectively improved clinical symptoms, menstruation, ovarian reserve function, hormonal balance, and pregnancy rate in patients with KDBSDOR-related infertility. This treatment is a potential alternative for women with DOR.</div><div>For a video summary of this article, see the Supplemental file 2 available online.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102576"},"PeriodicalIF":1.7,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Curcumin is widely investigated in tissue engineering and nanotechnology-enabled drug delivery, yet the rapidly expanding literature lacks a consolidated map to guide translation. To address this gap, we mapped global output, hotspots, and collaboration patterns on curcumin and aligned bibliometric trends with translational needs.
Methods
We conducted a Scopus-based bibliometric analysis of records published between 1997 and 2024 using a single-day snapshot (21 February 2025). A reproducible TITLE-ABS-KEY query centered on “curcumin” retrieved 12,327 documents. After retrieval, de-noising retained records that mentioned curcumin (or variants) in the title, abstract, or author keywords. We computed standard indicators (outputs, citations, subject areas, countries, institutions, authors, journals) and constructed keyword co-occurrence and collaboration networks in VOSviewer.
Results
Outputs increased sharply after 2016 and concentrated on pharmacology, biochemistry, materials science, and engineering. China (28.1 %), India (21.5 %), and the United States (12.6 %) led publication counts. Recurrent hotspots included bioavailability/controlled release, apoptosis/reactive oxygen species (ROS), hydrogels/nanofibers, and neuroprotection. Collaboration maps showed dense hubs around China, India, and the United States, while several regions were underrepresented.
Conclusion
Hotspots mirror experimental advances with nanocarriers such as PLGA, liposomes, and dendrosomes that improve curcumin stability, uptake, and therapeutic indices. Methodological transparency (single-source justification, query disclosure, de-noising) enhances reproducibility. Translational progress will benefit from harmonized in vivo models, full formulation reporting—size, polydispersity index (PDI), zeta potential, loading, and release—Good Manufacturing Practice (GMP)-compatible scale-up, and region-adapted regulatory guidance.
{"title":"The potential of curcumin in tissue engineering and nanotechnology-based drug delivery systems: A bibliometric analysis","authors":"Kaan ZIKŞAHNA , Rumeysa ADIYIL , Melisa ÖZKAN , Murat IHLAMUR","doi":"10.1016/j.eujim.2025.102575","DOIUrl":"10.1016/j.eujim.2025.102575","url":null,"abstract":"<div><h3>Introduction</h3><div>Curcumin is widely investigated in tissue engineering and nanotechnology-enabled drug delivery, yet the rapidly expanding literature lacks a consolidated map to guide translation. To address this gap, we mapped global output, hotspots, and collaboration patterns on curcumin and aligned bibliometric trends with translational needs.</div></div><div><h3>Methods</h3><div>We conducted a Scopus-based bibliometric analysis of records published between 1997 and 2024 using a single-day snapshot (21 February 2025). A reproducible TITLE-ABS-KEY query centered on “curcumin” retrieved 12,327 documents. After retrieval, de-noising retained records that mentioned curcumin (or variants) in the title, abstract, or author keywords. We computed standard indicators (outputs, citations, subject areas, countries, institutions, authors, journals) and constructed keyword co-occurrence and collaboration networks in VOSviewer.</div></div><div><h3>Results</h3><div>Outputs increased sharply after 2016 and concentrated on pharmacology, biochemistry, materials science, and engineering. China (28.1 %), India (21.5 %), and the United States (12.6 %) led publication counts. Recurrent hotspots included bioavailability/controlled release, apoptosis/reactive oxygen species (ROS), hydrogels/nanofibers, and neuroprotection. Collaboration maps showed dense hubs around China, India, and the United States, while several regions were underrepresented.</div></div><div><h3>Conclusion</h3><div>Hotspots mirror experimental advances with nanocarriers such as PLGA, liposomes, and dendrosomes that improve curcumin stability, uptake, and therapeutic indices. Methodological transparency (single-source justification, query disclosure, de-noising) enhances reproducibility. Translational progress will benefit from harmonized in vivo models, full formulation reporting—size, polydispersity index (PDI), zeta potential, loading, and release—Good Manufacturing Practice (GMP)-compatible scale-up, and region-adapted regulatory guidance.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102575"},"PeriodicalIF":1.7,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24DOI: 10.1016/j.eujim.2025.102574
Hong-bin Xie , Yuan Zhang , Jun-hong Guo , Ming-min Yang , Jia-jia Hu , Jie-wen Zhou , Da-hui Ma
Introduction
Dry eye disease (DED) is a chronic ocular surface disease that seriously affects quality of life. Traditional Chinese medicine (TCM) has prominent advantages in the treatment of DED. This study investigated the efficacy and safety of Chinese medicine Zhangyanming tablets (ZYMT) combined with fluorometholone eye drops (FED) and human epidermal growth factor eye drops (HEGFED) in the treatment of DED.
Methods
This was a randomized controlled study. A total of 122 patients with DED were randomly divided into the intervention group (n = 61) and the control group (n = 61). The control group received FED and HEGFED treatment (one drop twice daily), while the intervention group was given ZYMT (0.84 g orally, three times daily) in addition to the control group’s treatment. Both groups underwent 8 weeks of treatment. The primary outcome was the efficacy rate. The secondary outcomes included the mean change from baseline in the OSDI score and its subscales, tear film breakup time (BUT) and Schirmer’s test.
Results
After 8 weeks of treatment, the efficacy rate was 75.9 % (44/58) in the intervention group versus 54.2 % (32/59) in the control group (absolute difference 21.6 %, 95 % CI, 4.3 %∼37.2 %; risk ratio 1.40). The mean change from baseline in the OSDI score in the intervention group were significantly greater than those in the control group in week 8 (absolute difference -6.25, 95 % CI, -9.08∼-3.42). The mean changes from baseline in BUT, Schirmer’s test were significantly greater in the intervention group than that of the control group in both week 4 (BUT: absolute difference 2.49 s, 95 % CI, 1.82∼3.15 s; Schirmer’s test: absolute difference 1.11 mm/5 min, 95 % CI, 0.28∼1.95 mm/5 min) and week 8 (BUT: absolute difference 2.93 s, 95 % CI, 2.37∼3.49 s; Schirmer’s test: absolute difference 4.36 mm/5 min, 95 % CI, 3.88∼4.84 mm/5 min). No significant difference was observed in the safety profiles in these two groups (P > 0.05).
Conclusion
Compared to using FED and HEGFED alone, combined intervention of ZYMT can effectively ameliorate the eye symptoms of DED patients, and improve the efficacy rate.
{"title":"Effects of Zhangyanming tablet treating dry eye disease: A prospective, open-label, randomized controlled trial","authors":"Hong-bin Xie , Yuan Zhang , Jun-hong Guo , Ming-min Yang , Jia-jia Hu , Jie-wen Zhou , Da-hui Ma","doi":"10.1016/j.eujim.2025.102574","DOIUrl":"10.1016/j.eujim.2025.102574","url":null,"abstract":"<div><h3>Introduction</h3><div>Dry eye disease (DED) is a chronic ocular surface disease that seriously affects quality of life. Traditional Chinese medicine (TCM) has prominent advantages in the treatment of DED. This study investigated the efficacy and safety of Chinese medicine Zhangyanming tablets (ZYMT) combined with fluorometholone eye drops (FED) and human epidermal growth factor eye drops (HEGFED) in the treatment of DED.</div></div><div><h3>Methods</h3><div>This was a randomized controlled study. A total of 122 patients with DED were randomly divided into the intervention group (<em>n</em> = 61) and the control group (<em>n</em> = 61). The control group received FED and HEGFED treatment (one drop twice daily), while the intervention group was given ZYMT (0.84 g orally, three times daily) in addition to the control group’s treatment. Both groups underwent 8 weeks of treatment. The primary outcome was the efficacy rate. The secondary outcomes included the mean change from baseline in the OSDI score and its subscales, tear film breakup time (BUT) and Schirmer’s test.</div></div><div><h3>Results</h3><div>After 8 weeks of treatment, the efficacy rate was 75.9 % (44/58) in the intervention group versus 54.2 % (32/59) in the control group (absolute difference 21.6 %, 95 % CI, 4.3 %∼37.2 %; risk ratio 1.40). The mean change from baseline in the OSDI score in the intervention group were significantly greater than those in the control group in week 8 (absolute difference -6.25, 95 % CI, -9.08∼-3.42). The mean changes from baseline in BUT, Schirmer’s test were significantly greater in the intervention group than that of the control group in both week 4 (BUT: absolute difference 2.49 s, 95 % CI, 1.82∼3.15 s; Schirmer’s test: absolute difference 1.11 mm/5 min, 95 % CI, 0.28∼1.95 mm/5 min) and week 8 (BUT: absolute difference 2.93 s, 95 % CI, 2.37∼3.49 s; Schirmer’s test: absolute difference 4.36 mm/5 min, 95 % CI, 3.88∼4.84 mm/5 min). No significant difference was observed in the safety profiles in these two groups (<em>P</em> > 0.05).</div></div><div><h3>Conclusion</h3><div>Compared to using FED and HEGFED alone, combined intervention of ZYMT can effectively ameliorate the eye symptoms of DED patients, and improve the efficacy rate.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102574"},"PeriodicalIF":1.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24DOI: 10.1016/j.eujim.2025.102573
Catrina Davy , Michael Loughlin , John Hughes
Introduction
Ten sessions of acupuncture are recommended in the UK National Institute for Health and Care Excellence guidelines for the prophylactic treatment of migraines. However, ongoing or maintenance treatment is not recommended. Teaching people self-acupuncture (SA) may help people to manage their migraines. To date, there is no research examining SA in the management of migraines.
Methods
This study will examine the feasibility of all aspects of a trial of SA for patients who have previously found acupuncture beneficial to manage their migraines. This will include preliminary data on the size of any effect, participants’ views on the trial design and intervention, and any safety issues. The findings will determine the methodology for a subsequent RCT to examine the efficacy of SA to treat migraines.
The trial will employ a pragmatic, mixed-methods, randomised, parallel-group, exploratory design. The trial will compare SA plus standard care versus standard care alone. The trial aims to recruit 60 participants: 40 randomised to the SA group and 20 to the standard care group. Participants will be eligible if they have had a course of at least six acupuncture sessions to manage their migraines at the Royal London Hospital for Integrated Medicine, UK and found the treatments effective. Participants will complete outcome measures at various time points and take part in a qualitative interview to explore their views on the design of the trial and acceptability of SA. The researcher will observe and take field notes of the teaching session to explore the acceptability of the SA teaching method. Data will be analysed to determine if the trial design is feasible.
{"title":"A study protocol for a randomised feasibility trial of self-acupuncture for patients with migraines (SAM)","authors":"Catrina Davy , Michael Loughlin , John Hughes","doi":"10.1016/j.eujim.2025.102573","DOIUrl":"10.1016/j.eujim.2025.102573","url":null,"abstract":"<div><h3>Introduction</h3><div>Ten sessions of acupuncture are recommended in the UK National Institute for Health and Care Excellence guidelines for the prophylactic treatment of migraines. However, ongoing or maintenance treatment is not recommended. Teaching people self-acupuncture (SA) may help people to manage their migraines. To date, there is no research examining SA in the management of migraines.</div></div><div><h3>Methods</h3><div>This study will examine the feasibility of all aspects of a trial of SA for patients who have previously found acupuncture beneficial to manage their migraines. This will include preliminary data on the size of any effect, participants’ views on the trial design and intervention, and any safety issues. The findings will determine the methodology for a subsequent RCT to examine the efficacy of SA to treat migraines.</div><div>The trial will employ a pragmatic, mixed-methods, randomised, parallel-group, exploratory design. The trial will compare SA plus standard care versus standard care alone. The trial aims to recruit 60 participants: 40 randomised to the SA group and 20 to the standard care group. Participants will be eligible if they have had a course of at least six acupuncture sessions to manage their migraines at the Royal London Hospital for Integrated Medicine, UK and found the treatments effective. Participants will complete outcome measures at various time points and take part in a qualitative interview to explore their views on the design of the trial and acceptability of SA. The researcher will observe and take field notes of the teaching session to explore the acceptability of the SA teaching method. Data will be analysed to determine if the trial design is feasible.</div></div><div><h3>Trial registration information</h3><div>ClinicalTrials.gov <span><span>https://clinicaltrials.gov/study/NCT06716944?cond=migraine&intr=acupuncture&rank=1</span><svg><path></path></svg></span> NCT06716944</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102573"},"PeriodicalIF":1.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.1016/j.eujim.2025.102571
Chaohui Yan , Xi Luo , Yiwen Tang, Hong Chen, Shiting Qin, Yumei Huang, Chunhui Zeng, Ke Yang
Background
Novel, effective, and safe therapeutic strategies are urgently needed to overcome conventional acute lung injury (ALI) treatment limitations. This study combined network pharmacology and experimental verification to explore the relationship between Ampelopsin (APS) and ALI molecular pathways, and to elucidate the key mechanism of APS in attenuating ALI.
Methods
The Swiss Target Prediction, Traditional Chinese Medicine Systems Pharmacology, DisGeNET, and GeneCards databases were used to predict the targets of APS to attenuate ALI. Potential targets were imported into the Metascape database to perform protein-protein interaction network, Gene ontology, and Kyoto encyclopedia of genes and genomes analyses, and a “drug - target - disease - access network” was established. Molecular docking of APS with key targets was performed using PyMOL and AutoDock. Validation experiments were performed using a lipopolysaccharide (LPS)-induced ALI mouse model, LPS-induced inflammatory A549 cells, and molecular docking between active compounds of APS and potential targets.
Results
Network pharmacology analysis identified six key targets (AKT1, AKT2, epidermal growth factor receptor, HRAS, IGF1R, and KDR) of APS to attenuate ALI, which were mainly involved in biological processes, such as cell migration and movement, regulation of kinase activity, and PI3K-Akt signaling pathway. Molecular docking analysis revealed that APS binds the key targets with binding energy ranging from -4.37 to -2.26. Further experiments revealed that APS could reduce pulmonary edema by reducing inflammatory factor release and regulate oxidative stress and autophagy, thus protecting LPS-induced ALI mice and A549 cells.
Conclusions
APS regulates inflammation and oxidative stress via the PI3K-Akt signaling pathway, thus retarding ALI progression.
{"title":"Ampelopsin's mechanism in ameliorating acute lung injury: Insights from network pharmacology and experimental validation","authors":"Chaohui Yan , Xi Luo , Yiwen Tang, Hong Chen, Shiting Qin, Yumei Huang, Chunhui Zeng, Ke Yang","doi":"10.1016/j.eujim.2025.102571","DOIUrl":"10.1016/j.eujim.2025.102571","url":null,"abstract":"<div><h3>Background</h3><div>Novel, effective, and safe therapeutic strategies are urgently needed to overcome conventional acute lung injury (ALI) treatment limitations. This study combined network pharmacology and experimental verification to explore the relationship between Ampelopsin (APS) and ALI molecular pathways, and to elucidate the key mechanism of APS in attenuating ALI.</div></div><div><h3>Methods</h3><div>The Swiss Target Prediction, Traditional Chinese Medicine Systems Pharmacology, DisGeNET, and GeneCards databases were used to predict the targets of APS to attenuate ALI. Potential targets were imported into the Metascape database to perform protein-protein interaction network, Gene ontology, and Kyoto encyclopedia of genes and genomes analyses, and a “drug - target - disease - access network” was established. Molecular docking of APS with key targets was performed using PyMOL and AutoDock. Validation experiments were performed using a lipopolysaccharide (LPS)-induced ALI mouse model, LPS-induced inflammatory A549 cells, and molecular docking between active compounds of APS and potential targets.</div></div><div><h3>Results</h3><div>Network pharmacology analysis identified six key targets (AKT1, AKT2, epidermal growth factor receptor, HRAS, IGF1R, and KDR) of APS to attenuate ALI, which were mainly involved in biological processes, such as cell migration and movement, regulation of kinase activity, and PI3K-Akt signaling pathway. Molecular docking analysis revealed that APS binds the key targets with binding energy ranging from -4.37 to -2.26. Further experiments revealed that APS could reduce pulmonary edema by reducing inflammatory factor release and regulate oxidative stress and autophagy, thus protecting LPS-induced ALI mice and A549 cells.</div></div><div><h3>Conclusions</h3><div>APS regulates inflammation and oxidative stress via the PI3K-Akt signaling pathway, thus retarding ALI progression.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102571"},"PeriodicalIF":1.7,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-18DOI: 10.1016/j.eujim.2025.102572
Jiashan Li , Yuning Qin , Liyun He , Feifei Gao , Ziyan Li , Tingting Liu , Zezhi Fan , Yi Guo , Tianyi Zhao , Xue Zhao
Introduction
Patients with atrophic gastritis (AG) exhibit typical upper gastrointestinal symptoms. Although acupuncture therapy can alleviate some gastrointestinal symptoms, it remains challenging to determine the optimal intervention for various symptoms. This study aimed to use network meta-analysis (NMA) to compare the efficacy of acupuncture therapies for AG with upper gastrointestinal symptoms.
Methods
Twelve databases were systematically searched from inception to 25 November 2024 to identify randomized clinical trials or retrospective cohort studies that evaluated the efficacy of acupuncture therapies for AG with upper gastrointestinal symptoms. The primary outcomes were stomachache, flatulence, heartburn, hiccups, and appetite disorder (assessed using the traditional Chinese medicine syndrome score, numeric rating scale or visual analogue score), and acid reflux (assessed using the symptom score). The Cochrane Risk of Bias 2 tool was used to construct a risk-of-bias map. R 4.3.2 and JAGS 4.3.1 were used to conduct the NMA. The Confidence in NMA web application was used to assess the quality of evidence.
Results
The NMA analyzed 26 studies involving 3,076 participants. For flatulence, acupoint sticking therapy was ranked first (i.e., most effective), with a surface under the cumulative ranking curve (SUCRA) of 83.2 %, and low to very low certainty. Manual acupuncture was ranked first for acid reflux (SUCRA 87.19 %, low to very low certainty) and appetite disorder (SUCRA 67.5 %, moderate to very low certainty). Warm acupuncture plus traditional Chinese medicine was ranked first for stomachache (SUCRA 75.0 %, low to very low certainty), while western medicine was ranked first for hiccups (SUCRA 91.93 %, very low certainty). There were no significant differences in efficacy between many acupuncture therapies.
Conclusion
Patients with AG with flatulence may benefit from acupoint sticking therapy, while the symptoms of acid reflux or appetite disorder may be relieved through manual acupuncture. However, clinical decision-making should be combined with practical factors due to the limited number of significant differences in the efficacy of various acupuncture therapies.
{"title":"Acupuncture therapy for atrophic gastritis with upper gastrointestinal symptoms: A systematic review and network meta-analysis","authors":"Jiashan Li , Yuning Qin , Liyun He , Feifei Gao , Ziyan Li , Tingting Liu , Zezhi Fan , Yi Guo , Tianyi Zhao , Xue Zhao","doi":"10.1016/j.eujim.2025.102572","DOIUrl":"10.1016/j.eujim.2025.102572","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with atrophic gastritis (AG) exhibit typical upper gastrointestinal symptoms. Although acupuncture therapy can alleviate some gastrointestinal symptoms, it remains challenging to determine the optimal intervention for various symptoms. This study aimed to use network meta-analysis (NMA) to compare the efficacy of acupuncture therapies for AG with upper gastrointestinal symptoms.</div></div><div><h3>Methods</h3><div>Twelve databases were systematically searched from inception to 25 November 2024 to identify randomized clinical trials or retrospective cohort studies that evaluated the efficacy of acupuncture therapies for AG with upper gastrointestinal symptoms. The primary outcomes were stomachache, flatulence, heartburn, hiccups, and appetite disorder (assessed using the traditional Chinese medicine syndrome score, numeric rating scale or visual analogue score), and acid reflux (assessed using the symptom score). The Cochrane Risk of Bias 2 tool was used to construct a risk-of-bias map. R 4.3.2 and JAGS 4.3.1 were used to conduct the NMA. The Confidence in NMA web application was used to assess the quality of evidence.</div></div><div><h3>Results</h3><div>The NMA analyzed 26 studies involving 3,076 participants. For flatulence, acupoint sticking therapy was ranked first (i.e., most effective), with a surface under the cumulative ranking curve (SUCRA) of 83.2 %, and low to very low certainty. Manual acupuncture was ranked first for acid reflux (SUCRA 87.19 %, low to very low certainty) and appetite disorder (SUCRA 67.5 %, moderate to very low certainty). Warm acupuncture plus traditional Chinese medicine was ranked first for stomachache (SUCRA 75.0 %, low to very low certainty), while western medicine was ranked first for hiccups (SUCRA 91.93 %, very low certainty). There were no significant differences in efficacy between many acupuncture therapies.</div></div><div><h3>Conclusion</h3><div>Patients with AG with flatulence may benefit from acupoint sticking therapy, while the symptoms of acid reflux or appetite disorder may be relieved through manual acupuncture. However, clinical decision-making should be combined with practical factors due to the limited number of significant differences in the efficacy of various acupuncture therapies.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102572"},"PeriodicalIF":1.7,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-14DOI: 10.1016/j.eujim.2025.102570
Thang Truong Le , Tien-Dung Nguyen , Minh-Thuong Nguyen-Van , Tran Ngo Bao Huynh , Thuan-Thien Dinh , Chau Dao Minh Huynh , Phuc Dao Thien Nguyen , Tan Nguyen Van Ho , Hieu Tran-Van , Viet Hoang
Introduction
Candida albicans (C. albicans) infections pose a significant health challenge, necessitating the exploration of novel antifungal agents. Essential oils derived from medicinal plants play a crucial role in aromatherapy as a complementary therapeutic approach. This study aimed to investigate the molecular mechanisms of Melaleuca bracteata F. Mueall (M. bracteata) essential oil against C. albicans, establishing its potential as a novel plant-derived antifungal therapeutic in response to increasing antimicrobial resistance.
Methods
This study employed a comprehensive approach, combining chemical analysis, in vitro experiments, and computational methods to investigate the antifungal properties of M. bracteata essential oil against C. albicans.
Results
Gas Chromatography-Mass Spectrometry (GCMS) analysis revealed eugenol methyl ether (EME) as the predominant component (86.87 %) of M. bracteata essential oil. The oil demonstrated potent antifungal activity against C. albicans, with a Minimum Inhibitory Concentration (MIC) of 400 µg/mL. It significantly inhibited biofilm formation, with 96.03 % inhibition at MIC, and caused notable morphological changes in C. albicans cells as observed through Scanning Electron Microscope (SEM). Gene expression analysis showed the downregulation of key biofilm-related genes (efg1, als3, act1) upon treatment with the oil. Molecular docking suggested potential interactions of EME with critical C. albicans proteins. Importantly, the oil exhibited limited cytotoxicity against various mammalian cell lines. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictions indicated favorable pharmacokinetic properties for EME, while network pharmacology analysis suggested potential immunomodulatory effects.
Conclusions
These findings highlight the promising antifungal potential of M. bracteata essential oil, particularly EME, against C. albicans, warranting further investigation for its development as a novel therapeutic agent.
白色念珠菌（C. albicans）感染对健康构成重大挑战，需要探索新的抗真菌药物。从药用植物中提取的精油作为一种辅助治疗方法在芳香疗法中起着至关重要的作用。本研究旨在探讨白念珠菌（C. alaleuca bracteata F. Mueall， M. bracteata）精油抗白色念珠菌的分子机制，确定其作为一种新型植物源性抗真菌药物的潜力，以应对日益增加的抗生素耐药性。方法采用化学分析、体外实验和计算方法相结合的综合研究方法，研究苞叶分枝杆菌精油对白色念珠菌的抑菌作用。结果气相色谱-质谱（GCMS）分析显示，丁香酚甲醚（EME）为主要成分，占86.87%。该精油对白色念珠菌具有较强的抑菌活性，最低抑菌浓度（MIC）为400µg/mL。通过扫描电镜（SEM）观察，其显著抑制了生物膜的形成，MIC抑制率为96.03%，并引起白色念珠菌细胞形态的明显改变。基因表达分析显示，油处理后，关键生物膜相关基因（efg1, als3, act1）表达下调。分子对接提示EME可能与关键的白色念珠菌蛋白相互作用。重要的是，该油对多种哺乳动物细胞系显示出有限的细胞毒性。吸收、分布、代谢、排泄和毒性（ADMET）预测表明EME具有良好的药代动力学特性，而网络药理学分析表明EME具有潜在的免疫调节作用。结论这些研究结果表明，短苞草精油，特别是EME，对白色念珠菌具有良好的抗真菌潜力，值得进一步研究，以开发其作为一种新的治疗药物。
{"title":"Antifungal mechanisms of Melaleuca bracteata F. Mueall essential oil against Candida albicans: From chemical profiling to molecular targets","authors":"Thang Truong Le , Tien-Dung Nguyen , Minh-Thuong Nguyen-Van , Tran Ngo Bao Huynh , Thuan-Thien Dinh , Chau Dao Minh Huynh , Phuc Dao Thien Nguyen , Tan Nguyen Van Ho , Hieu Tran-Van , Viet Hoang","doi":"10.1016/j.eujim.2025.102570","DOIUrl":"10.1016/j.eujim.2025.102570","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Candida albicans (C. albicans)</em> infections pose a significant health challenge, necessitating the exploration of novel antifungal agents. Essential oils derived from medicinal plants play a crucial role in aromatherapy as a complementary therapeutic approach. This study aimed to investigate the molecular mechanisms of <em>Melaleuca bracteata</em> F. Mueall <em>(M. bracteata)</em> essential oil against <em>C. albicans</em>, establishing its potential as a novel plant-derived antifungal therapeutic in response to increasing antimicrobial resistance.</div></div><div><h3>Methods</h3><div>This study employed a comprehensive approach, combining chemical analysis, <em>in vitro</em> experiments, and computational methods to investigate the antifungal properties of <em>M. bracteata</em> essential oil against <em>C. albicans</em>.</div></div><div><h3>Results</h3><div>Gas Chromatography-Mass Spectrometry (GCMS) analysis revealed eugenol methyl ether (EME) as the predominant component (86.87 %) of <em>M. bracteata</em> essential oil. The oil demonstrated potent antifungal activity against <em>C. albicans</em>, with a Minimum Inhibitory Concentration (MIC) of 400 µg/mL. It significantly inhibited biofilm formation, with 96.03 % inhibition at MIC, and caused notable morphological changes in <em>C. albicans</em> cells as observed through Scanning Electron Microscope (SEM). Gene expression analysis showed the downregulation of key biofilm-related genes (<em>efg1, als3, act1</em>) upon treatment with the oil. Molecular docking suggested potential interactions of EME with critical <em>C. albicans</em> proteins. Importantly, the oil exhibited limited cytotoxicity against various mammalian cell lines. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictions indicated favorable pharmacokinetic properties for EME, while network pharmacology analysis suggested potential immunomodulatory effects.</div></div><div><h3>Conclusions</h3><div>These findings highlight the promising antifungal potential of <em>M. bracteata</em> essential oil, particularly EME, against <em>C. albicans</em>, warranting further investigation for its development as a novel therapeutic agent.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102570"},"PeriodicalIF":1.7,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145359469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号